Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

Oh J, Bar-Or A, Montalban X, Sormani MP, Weber MS, Reich DS.

DOI: 10.1016/s1474-4422(26)00141-9
Published: 2026-07-01
Container: Lancet Neurol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-26-00141-9,
  title = {Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.},
  author = {Oh J and  Bar-Or A and  Montalban X and  Sormani MP and  Weber MS and  Reich DS.},
  year = {2026},
  journal = {Lancet Neurol},
  doi = {10.1016/s1474-4422(26)00141-9},
  url = {https://doi.org/10.1016/s1474-4422(26)00141-9}
}

RIS

TY  - JOUR
TI  - Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.
AU  - Oh J
AU  -  Bar-Or A
AU  -  Montalban X
AU  -  Sormani MP
AU  -  Weber MS
AU  -  Reich DS.
PY  - 2026
JO  - Lancet Neurol
DO  - 10.1016/s1474-4422(26)00141-9
UR  - https://doi.org/10.1016/s1474-4422(26)00141-9
ER  -

APA

J, O., A, B., X, M., MP, S., MS, W., & DS., R. (2026). Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.. Lancet Neurol. https://doi.org/10.1016/s1474-4422(26)00141-9

Source records

europe-pmc · retrieved 2026-09-26T23:57:20.420Z